Navigation Links
TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
Date:12/2/2008

or new therapies that could offer patients less frequent dosing regimens and better tolerability."

The randomized, double-blind, placebo-controlled, in-clinic trial used a cross-over design to evaluate the efficacy, safety and tolerability of three doses of NGX267. A total of 26 patients with xerostomia associated with primary or secondary Sjogren's syndrome were enrolled at three sites in the United States. In four distinct treatment periods, each patient was randomized to receive a single dose of 10 mg, 15 mg and 20 mg of NGX267 and placebo. Patients remained in the clinic and serial efficacy assessments were taken at scheduled time points through 24 hours post dosing. For the primary endpoint, whole mouth salivary flow was collected by passive drainage into pre-weighed containers. Secondary endpoints included maximum change in salivary flow rate compared to predose and an 8-item salivary flow questionnaire completed by the patient that assessed the impact of dry mouth across various dimensions of patient functioning.

The 10 mg, 15 mg and 20 mg doses of NGX267 produced statistically significant increases in salivary flow compared to placebo across a number of time points, including the mean salivary flow production over the 24 hour post-dosing period (p=0.025, 0.001, and 0.001, respectively). In addition, the maximum change in salivary flow was statistically significant compared to placebo for each of the three doses of NGX267. Results of the 8-item patient self-assessment correlated with the quantitative results of salivary production. At the 15 mg and 20 mg doses, statistically significant differences compared to placebo were demonstrated in a variety of domains including items that rated improvement in speaking and swallowing, dryness of mouth and level of thirst.

Safety was monitored throughout the evaluation period and NGX267 was shown to be safe and well-tolerated. All patients completed all tr
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
2. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
3. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
4. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
5. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
6. Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
7. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Research and Markets has announced ... Forecast of Pharmaceutical Equipment Market in China, 2014-2018" ... Development Trend Forecast of Pharmaceutical Equipment Market in ... China,s pharmaceutical equipment industry in the aspects ... and business performance of domestic major enterprises, as well ...
(Date:8/29/2014)... 2014 According to the ... Services (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User ... Gene Synthesis, NGS, DNA, RNAi) - Global Forecast ... Synthesis Market is expected to reach $1,712.1 Million ... at a CAGR of 9.8% from 2014 to ...
(Date:8/29/2014)... 2014 /PRNewswire-iReach/ -- ChemImage will present a workshop focused ... Zealand Forensic Science Society,s 22 nd International ... Adelaide, Australia .  Forensic Scientists will be ... hyperspectral imaging can bring to examination procedures. ... of Product Development at ChemImage, will host a ...
Breaking Medicine Technology:Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
(Date:8/30/2014)... Aliso Viejo, California (PRWEB) August 30, 2014 ... have announced the release of the TransGhost plugin from ... frightening tool that gives users the ability to tell ... Austin, CEO of Pixel Film Studios. “Users will make ... to use transition plugin.” , With TransGhost users can ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 The SI ... nine mobilizations and six muscle energy techniques. Michael P. ... and demonstrates twenty-seven examination techniques for the SI Joint. ... supports Dr. Reiman's live course presentation with North American ... Applying a differential diagnosis approach to ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 The KSF ... Challenge and K.Warrior Search on November 8th, 2014 at ... years, these events have introduced many notorious and notable ... Strike-Force, IWF and the UFC. , Among these ... fighters leave its doors armed with the virtues of ...
(Date:8/30/2014)... Saturday 30 August 2014: The first multidisciplinary ... with acute coronary syndromes (ACS) are published today ... paper was written jointly by the European Heart ... (ACCA) and the European Association of Percutaneous Cardiovascular ... Professor Bulent Gorenek (Turkey), chairperson of the task ...
(Date:8/30/2014)... Saturday 30 August 2014: The first recommendations ... in pulmonary embolism are published today in new ... Congress by Professor Stavros V. Konstantinides (Germany/Greece) and ... Guidelines on the diagnosis and management of acute ... Heart Journal (1) and on the ESC Website. ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Released TransGhost Plugin for Final Cut Pro X Today 2Health News:Pixel Film Studios Released TransGhost Plugin for Final Cut Pro X Today 3Health News:North American Seminars Online PT Continuing Education Course, Examination and Treatment of the SI Joint, Receives Continuing Education Approval in NJ, CA, IL, PA, & TX 2Health News:KSF Presents US Open Challenge-K. Warrior Search, Seeking Inspirational Warrior Fighters Like Cung Le 2Health News:KSF Presents US Open Challenge-K. Warrior Search, Seeking Inspirational Warrior Fighters Like Cung Le 3Health News:KSF Presents US Open Challenge-K. Warrior Search, Seeking Inspirational Warrior Fighters Like Cung Le 4Health News:First multidisciplinary recommendations on management of arrhythmias in ACS patients 2Health News:First recommendations on all new oral anticoagulants in pulmonary embolism published 2
... April 23 (HealthDay News) -- It goes without saying that ... they can also be very expensive, an expert warns. ... a person bitten by a venomous snake, said Jill Heatley, ... in College Station. The total cost includes hospitalization, which ...
... The International and American Associations for Dental ... in children. These articles, titled "Hypoplasia-Associated Severe Early ... Page Caufield, New York University College of Dentistry) ... (lead author M.E.C. Elfrink, Academic Centre for Dentistry, ...
... destruction of the insulin-producing beta cells. Over 250,000 patients suffer ... daily insulin injections to maintain glucose metabolism. Replacement of the ... organ or isolated human beta cells is the only effective ... of organ donors this method can be offered to only ...
... St. Jude Children,s Research Hospital scientists have rewritten the ... it guards early brain cells from DNA damage. Such ... showed that cells in the developing brain require TopBP1 ... is copied prior to cell division. Investigators also reported ...
... That "brain freeze" headache you experience when eating ice cream ... change in brain blood flow, researchers report. What,s more, ... more troubling forms of headache such as migraine, the U.S. ... blood flow in 13 healthy adults as they sipped ice ...
... April 22 (HealthDay News) -- Tick season has started earlier ... gardeners and others who love the outdoors should take precautions ... People also should keep alert for symptoms of tick-borne ... tick-borne diseases such as Lyme disease, anaplasmosis and babesiosis -- ...
Cached Medicine News:Health News:Cost of Snakebite Therapy May Squeeze Victims' Wallets 2Health News:IADR/AADR publish studies on severe early childhood caries - proposes new classification 2Health News:IADR/AADR publish studies on severe early childhood caries - proposes new classification 3Health News:Xenotransplantation as a therapy for type 1 diabetes 2Health News:Protein prevents DNA damage in the developing brain and might serve as a tumor suppressor 2Health News:Protein prevents DNA damage in the developing brain and might serve as a tumor suppressor 3Health News:'Ice Cream Headaches' Might Offer Clues to Migraines 2Health News:Tick Season Starting Early This Year 2
... The Professional Gold Package is ... laboratory. The package includes the ... automated system, starter package accessory ... adapter, specimen mounts 1/2" head, ...
... Semi-Automatic Tissue Sectioning System has maintained the ... system. Researchers from around the globe have ... their fresh and fresh fixed tissue sectioning ... With the Vibratome Automatic Tissue Sectioning Systems, ...
... Plus Sectioning System provides a versatile means ... plant tissues. The 1000 employs a ... freezing or embedding. The creation of ... of enzyme activities, and other deleterious effects ...
... with a square vice mounting device. ... for mounting specimens and placing in ... blocks are annodized black for easy ... They are shipped three to ...
Medicine Products: